FDA Backs Moderna's First-of-its-Kind mRNA Flu Vaccine

What happened

Moderna submitted its mRNA-based seasonal influenza vaccine, called mFlusiva, for FDA review following positive phase 3 trial results. The agency set an action date of August 5 and received highly positive briefing documents ahead of its advisory committee meeting. However, the advisory committee raised questions about the study methodology, though it found no major deficiencies in the vaccine's efficacy. If approved, mFlusiva would become the first-ever mRNA-based flu vaccine and could launch for the 2026-2027 flu season. Separately, the European Commission approved Moderna's combination flu-and-COVID vaccine, mCOMBRIAX, for adults 50 and older last month.

Why the stock moved

Moderna's stock has climbed more than 100% this year following positive developments around its vaccine pipeline diversification. The FDA's favorable briefing documents and upcoming decision on mFlusiva represent a near-term catalyst for investors who have watched the company struggle after COVID-19 vaccine revenue declined. The potential approval signals that Moderna's mRNA platform can succeed beyond its pandemic product, addressing concerns that it was a one-trick pony. The combination vaccine approval in Europe adds further validation to the company's respiratory vaccine strategy.

Bigger picture

Moderna is aggressively pivoting from declining COVID-19 vaccine sales toward seasonal respiratory markets and other therapeutic areas. The company reported $389 million in revenue for the first quarter, up 260% year-over-year, but posted an adjusted loss of $1.18 per share as it invests heavily in research and development. With $7.5 billion in cash and minimal debt, Moderna has runway to fund multiple product launches expected between 2027 and 2028, including vaccines for norovirus and personalized cancer treatments developed with Merck. Management targets company-wide breakeven by 2028. The mRNA flu vaccine market represents a significant commercial opportunity, as bundling flu and COVID shots could improve patient compliance and create recurring revenue streams.

What investors watch

The August 5 FDA decision on mFlusiva is the immediate focus, as approval would validate Moderna's ability to compete in the established flu vaccine market. Investors should also monitor pivotal phase 3 data readouts expected later this year for the company's personalized cancer vaccine developed with Merck, which could transform Moderna's long-term valuation beyond infectious diseases. Any updates on the combination vaccine's U.S. approval timeline and commercial performance in Europe will provide insights into market adoption. Finally, quarterly cash burn rates and progress toward the 2028 breakeven target will remain critical indicators of financial sustainability.